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Stenosis associated with neointimal hyperplasia plays a key role in 
the failure of synthetic hemodialysis vascular grafts. It was 
demonstrated that the local delivery of paclitaxel coated on the graft 
effectively prevented this stenosis. Because more than half of stenosis 
cases arise within 3 cm of the venous anastomosis, we coated the 
terminal part of the expanded polytetrafluoroethylene (ePTFE) grafts 
with paclitaxel to minimize the drug dose and systemic toxicity. We 
evaluated the effectiveness of this new design in a pig model. The 
terminal part of the ePTFE graft was dip-coated with paclitaxel at a 
dose of 0.58 μg/mm2, the total amount of paclitaxel loaded on the graft 
was 0.66 mg. 
A 15 cm-long ePTFE graft was surgically implanted between the 
common carotid artery and external jugular vein in 8 female Landrace 
pigs. Animals received grafts coated with paclitaxel and were sacrificed 
6 weeks after graft placement. Histomorphometric analysis was 
performed to compare the neointimal areas and the percentages of 
luminal stenosis between the coated group and the control group.  
Paclitaxel-coated vascular grafts significantly suppressed neointimal 
hyperplasia compared with the control group (P = 0.026). Whereas 7 of 
ii 
 
8 paclitaxel-coated grafts were patent, only 1 of the 6 control grafts was 
patent. The mean ± standard error values of the percentage of luminal 
stenosis were 26.9 ± 5.1 % (coated group) and 75.7 ± 12.7 % (control). 
The values for the neointimal area were 3.99 ± 1.01 mm2 (coated 
group) and 8.77 ± 1.66 mm2 (control).  
Despite the lower amount of drug loading used in the present study, 
paclitaxel coating on the terminal part of ePTFE hemodialysis grafts 
effectively reduced neointimal hyperplasia at the venous anastomosis. 
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Millions of patients with end-stage renal disease must receive 
chronic hemodialysis treatments throughout their lives. Hemodialysis 
vascular graft implantation is a vital procedure for securing vascular 
access in these patients; this is particularly true in patients such as the 
elderly and diabetic patients in whom a native arteriovenous (AV) 
fistula cannot be sufficiently developed. However, the prevalence of 
synthetic grafts made of expanded polytetrafluoroethylene (ePTFE) has 
decreased because of hemodialysis vascular access dysfunction with 
venous stenosis due to the aggressive development of neointimal 
hyperplasia at the graft-vein anastomosis, which subsequently results in 
thrombosis. Synthetic vascular grafts exhibit low patency: 50 % at 1 
year and 25 % at 2 years [1]. Despite various attempts to prevent 
stenosis in vascular grafts, none of these attempts has been successful 
in clinical trials [2]. 
The bio-incompatibility of ePTFE graft material, vascular injury 
through a surgical incision and hemodynamic shear stress at the vein-
graft anastomosis were shown to induce an inflammatory response and 
to play a role in the process of stenosis and thrombosis [3, 4]. 
Histologically, neointimal hyperplasia arising from a vascular graft is 
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characterized by the presence of smooth muscle cells and 
myofibroblasts, angiogenesis, and matrix deposition [5, 6]. Unlike 
neoplastic cells, these cells do not metastasize and mostly proliferate at 
the venous and arterial anastmosis only. Accordingly, suppressing the 
proliferation and migration of smooth muscle cells/myofibroblasts 
might be a logical approach to improving vascular graft outcome. Since 
systemically delivered drugs have shown little effect on graft failure [7], 
the approach of using antiproliferative agents such as paclitaxel and 
sirolimus locally deserves consideration for the reduction of neointimal 
hyperplasia. 
Paclitaxel is a potent anti-proliferative agent that interferes with the 
disassembly of microtubules in cell division, effectively inhibits the 
proliferation of vascular smooth muscle cells, and prevents neointimal 
hyperplasia in both hemodialysis vascular grafts and stents [8-10].  
We have previously demonstrated that the paclitaxel coating on an 
ePTFE graft reduced venous neointimal hyperplasia in a pig model [11, 
12]. Because more than half of vascular stenosis cases occur within 3 
cm of the venous anastomosis, we have developed a new design in this 
study in which both ends of the ePTFE graft were coated with 
paclitaxel and can therefore be directly applied at each of the 
anastomosis sites. After coating paclitaxel only on the terminal part of 
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2. Materials and methods 
  
Materials and graft preparation 
Paclitaxel was purchased from Samyang Genex Co. (Seoul, South 
Korea) and the ePTFE grafts were supplied by Bard peripheral Vascular, 
Inc. (Arizona, USA). All other chemicals and reagents were of 
analytical grade. 
Paclitaxel easily dissolves in tert-butanol to a concentration of 1 
mg/mL in a polypropylene tube. The terminal part of the ePTFE 
vascular graft was dipped gradually into the paclitaxel solution and was 
held to the surface in the vertical direction for 1 minute. The coating 
solution rapidly permeated but slowly diffused into the ePTFE grafts. 
Hence, only 3 cm of the ePTFE graft was paclitaxel-coated and drying 
occurred immediately after the graft was removed from the solution. 
The opposite end of the ePTFE graft was coated with paclitaxel in the 
same way. The paclitaxel-coated graft was dried under vacuum 
overnight to completely remove the coating solution.  
The concentration of paclitaxel at both 3 cm ends of an ePTFE graft 
was 0.58 μg/mm2 and the total loading amount of drug in a graft was 
0.66 mg. All grafts were sterilized in ethylene oxide before 
implantation. 




The surface morphologies on the inside and outside of the ePTFE 
graft were analyzed by a scanning electron microscope, JEOL (Tokyo, 
Japan). We compared the surfaces of each ePTFE graft before and after 
paclitaxel coating. 
 
in vitro release test 
For the in vitro release test, we used release medium composed of 
phosphate-buffered saline (PBS, pH 7.4) and 0.05 % (w/v) Tween 20. 
Paclitaxel-coated ePTFE grafts of 3 cm length were soaked in conical 
tubes with 10 mL release medium and incubated in a 37 °C/20 rpm 
hybridization incubator, FINEPCR (Seoul, South Korea). At each 
designated time over 28 days, grafts were moved into new conical 
tubes containing fresh release medium and the existing solution was 
analyzed by high-performance liquid chromatography (HPLC), Agilent   
(California, USA) using a 4.6 × 150-mm C18 reverse phase column. 
The mobile phase used was acetonitrile/water (50/50, v/v) under 
isocratic conditions at a flow rate of 0.8 mL/min. The UV detector was 
set at 227 nm and the retention time of paclitaxel was 9.5 min. 
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Experimental animals and surgical procedure 
This procedure which shows below was performed basically via the 
procedure of my previous study in the same way [13]. 
Eight female Landrace pigs weighing 50 kg ± 7 received paclitaxel-
coated grafts. Hemodialysis ePTFE grafts were placed between the 
common carotid artery and the external jugular vein in the lateral side 
of the neck along the sternocleidomastoid muscle. We performed the 
animal experiments according to the pig model proposed by Rotmans et 
al [14]. 
Animals were given ketamine HCl (20 mg/kg) and xylazine HCl (2 
mg/kg) for genenal anesthesia. The endotracheal anesthesia was 
maintained with isoflurane (2 %), and vecuronium bromide (0.1 mg/kg) 
was injected into an ear vein. Heparin (100 IU/kg) was injected before 
vessel manipulation. The common carotid artery was clamped using 
vessel loops and an end-to-side anastomosis was made at ~45° using 6-
0 polypropylene sutures. Venous anastomosis was created in a similar 
manner. Clopidogrel (75 mg/day) and aspirin (100 mg/day) were given 
to animals from day 0 until the day of euthanasia. 
Animals were euthanized 6 weeks after surgery. Until then, the 
animals were maintained in standard animal care facilities at Samsung 
Biomedical Research Institute (SBRI) and all procedures regarding the 
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surgery were performed according to the ‘Guidelines of the Care and 
Use of Laboratory Animals (National Institutes of Health Publication. 
No 85-23, revised 2001).  
At 6 weeks after surgery, the implanted grafts and adjacent vessels 
were excised and were immediately placed in heparin-containing PBS 
(10,000 IU/L) to prevent blood clots in the vessels. Subsequently, grafts 
were immersed and fixed in 10 % neutral-buffered formalin (NBF) for 
at least 24 hours.  
 
Tissue preparation and histomorphometric analysis 
This analysis methods are same with my previous study [13]. 
Paraffin-embedded tissue specimens were prepared and sections 
were cut perpendicular to the direction of blood flow and obtained 
serially into 5-micron thick slices at the 3 parts of the anastomosis 
(Figure 1). Masson’s trichrome stain was used for histomorphometric 
analysis. The neointima stained as pale blue inside of the vascular 
media, which was visualized as a layer of thick red fibers. 
We analyzed the neointimal areas and the percentage of luminal 
stenosis on each slide to compare the progress of stenosis between the 
coated group and control group which comes from the reference 13. 
The neointimal and the entire luminal areas were measured at 3 cross-
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sections around the center of the venous anastomosis using captured 
images obtained with an Aperio ImageScope, Aperio (California, USA). 
The percentage of luminal stenosis was calculated using the following 
formula (1.1). The mean values of the neointimal areas and the 




% 𝑜𝑜𝑜𝑜 𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙 𝑠𝑠𝑠𝑠𝑠𝑠𝑙𝑙𝑜𝑜𝑠𝑠𝑙𝑙𝑠𝑠                                 
= the  neointimal  area
the  neointimal  area +the  entire  luminal  area  




The neointimal areas and the percentage of luminal stenosis are 
expressed as means ± standard errors. Continuous data of the in vitro 
release test are presented as means ± standard deviations. We used 
repeated measures analysis of variance (ANOVA) to compare the in 
vitro release of paclitaxel from the 2 kinds of paclitaxel-coated grafts. 
The patency rates of the paclitaxel coated group and the control group 
were compared using Fisher’s exact test. Unpaired Student t-tests were 
used to compare the percentages of luminal stenosis and neointimal 
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areas between the 2 groups. P-values < 0.05 were considered statically 
significant. We used SPSS 18.0 for Windows (SPSS Inc., USA) for all 























Characterization of paclitaxel-coated ePTFE grafts 
We developed the drug coating method in order to coat both ends of 
the ePTFE graft selectively. Acetone, in which the paclitaxel easily 
dissolves, permeates and diffuses quickly to the ePTFE graft. Thus, it is 
difficult to control the selective coating of the drug on the terminal part 
of the ePTFE graft using acetone. Although dimethyl sulfoxide 
(DMSO) is also a good solvent for paclitaxel, it cannot penetrate the 
wall of the ePTFE graft. In contrast, paclitaxel is well dissolved in tert-
butanol, which is rapidly absorbed in the ePTFE graft and slowly 
diffuses to the other part of the ePTFE graft. Therefore, tert-butanol 
was chosen to coat paclitaxel selectively on the terminal parts of the 
ePTFE grafts. 
The surface morphology of the ePTFE grafts was compared to verify 
whether graft degenerated from the solvent. We confirmed that the 
surface of the ePTFE graft was not affected by contact with tert-butanol 
(Figure 2). 
 
in vitro release profiles of paclitaxel 
Figure 3 shows the in vitro release profiles of paclitaxel-coated grafts. 
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To confirm the differences in the in vitro drug release patterns 
according to the coating method, 2 types of paclitaxel-coated grafts 
with similar drug loading properties were prepared. The first type of 
graft was made by the gradual dipping method using tert-butanol as 
described above, and the other type of graft was made by the dipping 
method in acetone used in previous experiments [11]. For selective 
paclitaxel coating on the terminal region of the graft, 3 cm of the 
ePTFE graft was gradually immersed in the paclitaxel-dissolved tert-
butanol for 1 min. On the other hand, the total ePTFE graft was dipped 
and incubated in the paclitaxel-dissolved acetone for 30 min. 
When gradual dipping method with tert-butanol was used, the initial 
burst of paclitaxel was greater than 50 % of the loading amount. The 
released amount gradually increased afterward and the cumulative drug 
release for 28 days was close to 70 %. On the other hand, the 
cumulative drug release amount from the paclitaxel-coated grafts made 
by acetone dipping was less than 25 % of the initial loading. 
 
Animal experiments and histomorphometric analysis 
All animals survived until they were sacrificed without any evidence 
of necrosis, edema, or infection around the implanted grafts. 
Furthermore, all grafts incorporated into the surrounding tissue. Cross-
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sections of the venous anastomosis 6 weeks after surgery from the 8 
paclitaxel-coated grafts and the 6 uncoated grafts were stained with 
Masson’s Trichrome for identifying neointimal hyperplasia.   
Seven of the 8 paclitaxel-coated grafts were patent, even though 
some degree of neointimal hyperplasia was observed on the luminal 
surface of the graft wall (Figure 5). In contrast, according to the control 
results [13], only 1 of the 6 control grafts was patent and the lumen of 
the 5 grafts was nearly occluded by neointimal growth (Figure 4). 
Therefore, the patency of the paclitaxel-coated grafts was higher than 
that of the uncoated grafts (P = 0.026, Fisher’s exact test).  
Of the 8 grafts in the coated group, 4 showed several neointima on 
the graft wall and 3 exhibited some degree of neointima on the graft 
wall. Only 1 graft was entirely occluded by thrombosis; those blood 
clots were probably due to excessive bleeding just after surgery (Figure 
5G). 
For quantitative analysis of neointimal hyperplasia, the percentages 
of luminal stenosis and neointimal areas at the cross-section of the 
graft-venous anastomosis site were measured in both groups (Figure 6). 
The mean ± standard error values for the percentages of luminal 
stenosis were 75.7 ± 12.7 % in the control group and 26.9 ± 5.1 % in 
the paclitaxel-coated group. The percentages of luminal stenosis were 
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significantly lower in the paclitaxel-coated group than in the control 
group (P = 0.004, unpaired Student t-test). Similarly, the mean ± 
standard error values of neointimal areas were 8.77 ± 1.66 mm2 in the 
control group and 3.99 ± 1.01 mm2 in the coated group. Despite the 
variation in vessel thickness between the experimental animals, the 
neointimal areas of the coated group were significantly decreased 



















Paclitaxel coating of ePTFE grafts is reportedly effective in 
suppressing neointimal hyperplasia and stenosis, as shown in our 
previous studies [11, 12]. However, the appropriate coating amount of 
the drug and the suitable coating area for effective prevention of vessel 
narrowing has not been studied. If possible, decreasing the loading 
amount of the drug is desirable to avoid overdose. We achieved local 
delivery of paclitaxel on both ends of the ePTFE grafts using the 
gradual dipping method in the present study, proving that the paclitaxel 
coating on the terminal region of vascular grafts effectively suppresses 
neointimal hyperplasia in the venous anastomosis site in an animal 
model. 
The variables that affect the loading amount of drug include the 
coating length and the coating dose per unit area of the ePTFE graft. In 
this study, the dose of paclitaxel in the unit area was 0.58 μg/mm2 and 
the total amount of coated paclitaxel in an ePTFE graft was 0.66 mg, 
which is similar or lower than the doses used in other perivascular 
studies [10, 15-16]. Because this amount is less than 1 % of the amount 
used for chemotherapy, local side effects or systemic toxicity from 
paclitaxel is not expected to occur. 
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Given that the high blood flow and manipulation during surgery can 
cause thickening of the venous wall at the graft-venous anastomosis 
site, some neointima may appear at the venous region of the cross-
section (Figure 5 A, E). In contrast, the paclitaxel coating on the graft 
suppressed the neointimal growth on the graft wall. As a results, a few 
neointima were found on the graft wall in 4 of 8 samples (Figure 5 A, B, 
C, E) and 3 of these had neointimal growth on the graft wall (Figure 5 
D, F, H), even though these grafts were patent. Therefore, the loading 
amount of paclitaxel on the ePTFE graft was presumably lower than the 
sufficient dose for suppression of neointimal hyperplasia on the graft 
wall. 
Among the 8 paclitaxel-coated grafts, only 1 graft was occluded by 
thrombosis (Figure 5G). More than 90 % of thrombosed arteriovenous 
grafts were caused by stenosis due to neointimal hyperplasia either at 
the venous anastomosis site or in the proximal vein. However, if the 
region of the anastomosis site was occluded by thrombosis, stenosis 
also occurred in another part of the implanted graft. Therefore, the 
patency rate was calculated by including the thrombosed graft, whereas 
the percentages of luminal stenosis and neointimal areas were analyzed 
by excluding the thrombosed graft. 
We compared the in vitro release profiles of 2 types of paclitaxel-
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coated ePTFE grafts (Figure 3). Because paclitaxel-dissolved acetone 
permeated into the ePTFE graft wall easily and evaporated very fast   
and the coating process lasted for 30 min, paclitaxel was thought to be 
coated in the graft wall homogeneously. However, gradually dipping a 
3-cm length of vascular graft into the paclitaxel-dissolved tert-butanol 
resulted in adequate permeation into ePTFE graft wall but evaporation 
was slower than acetone because the boiling point of tert-butanol is 
82~83 °C. In addition, the coating process was terminated at 1 min and 
the graft was immediately dried; thus the coating solution may had not 
enough time to seep inside the graft wall and the drug may not have  
coated the outer surface of the graft wall uniformly. As a result, a 
greater initial burst release of paclitaxel was observed in the grafts 
made by the gradual dipping method compared to the grafts coated by 
acetone dipping. In the case of the arteriovenous graft, whether the 
initially released paclitaxel is more efficient for suppression of 
neointimal hyperplasia at the early tissue response or whether the long-
term release of the drug provides better results for stenosis has not been 
validated clinically. The results of long-term animal experiments are 
required to clarify this. However, the weight of pigs, which is 
proportional to the thickness of their vein, can change greatly over a 
period of several weeks. This may distort the experimental results for 
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paclitaxel coating and is a limitation of this animal model. 
The results of these animal experiments are comparable to other 
studies regarding the local delivery of paclitaxel or sirolimus. Unlike 
other perivascular experiments [10, 15-16], paclitaxel coating on the 
terminal part of the ePTFE graft does not require additional materials or 
care during surgery. Therefore, paclitaxel-coated vascular grafts on the 
terminal part of the ePTFE might reduce the risk of infection and 
unwanted tissue responses compared with other perivascular methods. 
The determination of the coating dose and the release rate of the drug 
are very important for suppression of neointimal hyperplasia in the 
venous anastomosis site. Therefore, further experiments that involve 
increasing the loading amount of paclitaxel on the ePTFE graft by 
extending the coating length of the terminal region or by increasing the 
coating dose per unit area of the vascular graft are necessary. In 











Paclitaxel coating on the terminal part of ePTFE vascular grafts 
significantly suppressed stenosis caused by neointimal hyperplasia, 
suggesting that drug delivery onto the terminal part of grafts is an ideal 
approach. This concept can easily be applied to clinical trial because 
reducing the coating amount of the drug is associated with improved 
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Figure 1. Diagram of a graft-venous anastomosis. The 3 cross-
sections were obtained to measure the progress of neointimal 
hyperplasia. One section was obtained at the center of the anastomosis 
(b); the others were obtained 2 mm to the proximal side (a) and 2 mm 
to the distal side (c) of the center of the anastomosis. The mean values 
of 3 cross-sections were calculated and used to compare the progress of 
neointimal hyperplasia between the paclitaxel-coated group and the 
control group. 
 








Figure2. Scanning electron microscope images of the uncoated 
ePTFE graft (A- inside, B- outside) and the paclitaxel-coated ePTFE 












Figure 3. Cumulative in vitro release profiles from 2 kinds of 
paclitaxel-coated grafts made by the dipping method using acetone and 
by the terminal coating method using tert-butanol (P < 0.001 by 
repeated measures analysis of variance). Data represent the means of 5 














Figure 4. Cross-sections of a venous anastomosis 6 weeks after 
placing grafts in the control group (Masson trichrome stain) from my 
previous study in 2012 [13]. The intima was detected as a pale blue 
















Figure 5. Cross-sections of a venous anastomosis 6 weeks after 
placing grafts in the coated group (Masson trichrome stain). The 
development of neointimal hyperplasia in the coated grafts was 




















Figure 6. Comparisons of the percentages of luminal stenosis (A) 
and the neointimal areas (B) in the coated group of this study and the 
control from the reference 13. Two parameters between the coated and 
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8. Abstract in Korean (국문초록) 
 
신장말기 환자들이 혈액투석을 하기 위해서는 안정적인 혈관 접근
로가 필요하다. 자가 혈관을 이용한 접근 방법이 가장 선호되는 방
법이나, 고령의 환자들이나 당뇨병 환자들처럼 혈관이 좁은 환자들
에게는 주로 인공혈관을 이용한 접근법이 시행된다.  
그러나, 주로 expanded polytetrafluoroethylene (ePTFE)재질로 
만들어지는 인공혈관은 1년에 50 %, 2년에 25 %의 낮은 개존률을 
나타낸다. 인공혈관을 이용한 접근로는 주로 정맥 문합 부위의 협착
으로 인하여 사용이 중단된다. 협착은 주로 평활근 세포와 근섬유아
세포로 이루어진 신내막 과증식에 의하여 발생하며, 후에 혈전이 생
성되는 단계로 이어져 혈액의 흐름을 차단한다.  
이번 연구에서, 인공혈관의 문합부위에서 발생하는 협착 및 신내
막 과증식을 막기 위한 약물 전달 시스템을 개발하였다. 세포 증식
을 억제하는 약물인 파클리탁셀을 인공혈관의 말단 부위에 국소적
으로 코팅하였다.  
파클리탁셀이 코팅된 인공혈관의 신내막 증식의 억제 효과를 확
인하기 위하여, 돼지 모델을 이용한 동물실험을 진행하였다. 6 주간
의 실험에서, 약물이 코팅된 인공혈관의 개존률은 대조군에 비해 증
가하였다. 문합 부분의 신내막 면적과 협착률 역시 대조군(75.0 ± 
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10.5 %, 7.5 ± 1.7 mm2) 에 비해 약물이 코팅된 인공혈관(26.8 
± 6.6 %, 3.4 ± 1.0 mm2 )에서 현저하게 줄어들었다.  
이번 실험에서, 적은 양의 약물을 사용하였음에도 불구하고, 인공혈
관 말단 3 cm의 약물 코팅은 신내막 과증식을 억제하는데 효과가 
있음을 확인하였다. 
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